Boya Bio-pharmaceutical Group Co Ltd operates in the Biological products exc. diagnostic sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Boya Bio-pharmaceutical Group Co Ltd with three other
companies in this sector in China:
Beijing SL Pharmaceutical Co Ltd
sales of 1.01 billion Chinese Renmimbi [US$152.57 million]
of which 98%
was Pharmaceuticals Industry),
Walvax Biotechnology Company Limited
(590.16 million Chinese Renmimbi [US$89.16 million]
of which 38%
was Autonomous Vaccine), and
Tianjin Ringpu Bio-Technology Co Ltd
(969.68 million Chinese Renmimbi [US$146.50 million]
of which 63%
was Veterinary Biological Products).
Boya Bio-pharmaceutical Group Co Ltd reported sales of 946.57 million Chinese Renmimbi (US$143.01 million)
December of 2016.
increase of 74.3%
versus 2015, when the company's sales were 543.10 million Chinese Renmimbi.
Sales at Boya Bio-pharmaceutical Group Co Ltd have increased during each of the previous five years
(and since 2011, sales have increased a total of 381%).
Sales of Bio-Pharmaceuticals saw an increase
that was more than double the company's growth rate: sales were up
1,065.6% in 2016, from
18.56 million Chinese Renmimbi to 216.29 million Chinese Renmimbi.